ERBB2 and cancer: Since IFN-γ has been shown to exhibit inhibitory effects on HER2 expression in cancer cells in vitro[31], we investigated whether the increased IFN-γ in the CM from the co-treatment of cancer cells with PBMCs and trastuzumab has a role in the cancer cell HER2 downregulation.